Novartis Pharmaceuticals Corporation offers several programs that can help adult patients with newly diagnosed FLT3+ acute myeloid leukemia (AML) who are prescribed RYDAPT® (midostaurin) capsules access treatment, as well as help eligible patients with out-of-pocket co-pay costs.
RYDAPT NOW Access Program
If your doctor prescribes RYDAPT for newly diagnosed FLT3+ AML based on the approved label and there is a delay in your insurance coverage as you transition out of the hospital, you may be eligible to receive a free 14-day supply of RYDAPT shipped directly to your home to avoid disruption in your treatment.
No purchase of RYDAPT is required. Novartis cannot guarantee that every patient who enrolls in RYDAPT NOW will be successful in obtaining insurance coverage for treatment.
RYDAPT NOW—a partner during your journey
Novartis Patient Assistance Now Oncology and the whole team at RYDAPT NOW are here to help you navigate the path along your treatment journey.
During AML treatment with RYDAPT, Care Coordinators are there to support you by:
Assisting you with access to RYDAPT as you transition between inpatient and outpatient settings
Offering support with insurance verification to help you understand how to get your medicine and what your financial responsibilities are
- Providing information about prior authorization requirements
- Initiating a benefits investigation in the inpatient setting in preparation for transitioning to the outpatient setting
Helping you find a pharmacy based on your insurance plan, and get your medicine according to your plan's guidelines
Providing information about financial assistance that may be available
Novartis cannot guarantee that every patient who enrolls in RYDAPT NOW will be successful in obtaining insurance coverage for treatment or will receive financial assistance.
Call 1-800-282-7630 for information on how to enroll in RYDAPT NOW and to learn more about the ways we can help.